InsiderTrades.com logo
René Russo net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

René Russo Biography and Net Worth

President & CEO of Xilio Therapeutics

Dr. Russo is an accomplished biotechnology CEO with over 25 years of experience leading R&D and commercialization in the biopharmaceutical industry across a range of therapeutic areas, including oncology. As an executive leader, Dr. Russo has led successful teams from early discovery research through all phases of clinical development, registration, and commercialization to bring multiple innovative therapies to patients across the United States and Europe. Dr. Russo also played a key role in helping to build Cubist Pharmaceuticals, a leading global anti-infective company that Merck acquired for $9.6B in 2015. In addition to Xilio’s board of directors, Dr. Russo serves as founder and executive chair of Ropirio Therapeutics, a member of the board of directors of Leyden Labs and PRxCision. Dr. Russo also serves on the board of trustees of Tufts Medical Center, the Boston Ballet and Life Science Cares Boston. Dr. Russo holds a B.S. in pharmacy and a Doctor of Pharmacy degree from Rutgers University and completed a post-doctoral fellowship with Bristol-Myers Squibb.

What is René Russo's net worth?

The estimated net worth of René Russo is at least $184.66 thousand as of June 16th, 2025. Dr. Russo owns 20,083 shares of Xilio Therapeutics stock worth more than $184,663 as of September 23rd. This net worth estimate does not reflect any other investments that Dr. Russo may own. Learn More about René Russo's net worth.

How do I contact René Russo?

The corporate mailing address for Dr. Russo and other Xilio Therapeutics executives is 828 Winter Street, Waltham, MA, 02451. Xilio Therapeutics can also be reached via phone at (617) 833-1027 and via email at [email protected]. Learn More on René Russo's contact information.

Has René Russo been buying or selling shares of Xilio Therapeutics?

René Russo has not been actively trading shares of Xilio Therapeutics during the last quarter. Most recently, on Monday, June 16th, René Russo bought 2,592 shares of Xilio Therapeutics stock. The stock was acquired at an average cost of $9.52 per share, with a total value of $24,675.84. Following the completion of the transaction, the chief executive officer now directly owns 20,083 shares of the company's stock, valued at $191,190.16. Learn More on René Russo's trading history.

Who are Xilio Therapeutics' active insiders?

Xilio Therapeutics' insider roster includes Christopher Frankenfield (CFO & COO), René Russo (President & CEO), and James Shannon (Director). Learn More on Xilio Therapeutics' active insiders.

René Russo Insider Trading History at Xilio Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/16/2025Buy2,592$9.52$24,675.8420,083View SEC Filing Icon  
See Full Table

René Russo Buying and Selling Activity at Xilio Therapeutics

This chart shows René Russo's buying and selling at Xilio Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Xilio Therapeutics Company Overview

Xilio Therapeutics logo
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $9.21
Low: $8.94
High: $9.04

50 Day Range

MA: $9.03
Low: $8.31
High: $9.50

2 Week Range

Now: $9.21
Low: $6.47
High: $12.74

Volume

1,114 shs

Average Volume

35,987 shs

Market Capitalization

$60.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A